Non Celiac Gluten Sensitivity, DBPCFC in Adolescents
Study Details
Study Description
Brief Summary
In a population based on healthy adolescents we will conduct a double blind placebo controlled food challenge (DBPCFC) with cross-over to identify patients with NCGS as recommended by the socalled Salerno criteria. It will take place at Hans Christian Andersen Childrens Hospital at Odense University Hospital, Denmark in October-November 2020.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Non Gluten Sensitivity, a double blind placebo controlled food challenge with cross-over in healthy Danish Adolescents
Caecilie Crawley, Nadia Savino, Cecilie Halby, Stine Dydensborg Sander, Anne-Marie Nybo Andersen, Joseph Murray, Robin Christensen, Steffen Husby
INTRODUCTION Non-celiac gluten sensitivity (NCGS) is a newly described disease entity, where the individual shows signs of sensitivity to gluten, but with no evidence of IgE-mediated wheat allergy or CD (1). The extent and severity of NCGS is so far an enigma (2), but symptoms of NCGS may be commonly occurring, with a reported prevalence of up to 6% of the adult population (3). So far, only ten studies with a double-blind placebo-controlled food challenge have been performed showing divergent study outcomes due to different study designs and methods and a significant nocebo/placebo effect. In general, the studies are characterized by patient recruitment from a gastroenterological clinic limited to adults (4). Our study stands out in this respect, as we will investigate an unselected group of patients as adolescents (not recruited from an outpatient clinic), because patients with NCGS often report that their symptoms started at that time.
Several researchers have concluded that patients with NCGS may not react to gluten but instead to dietary carbohydrates, so-called FODMAPS or amylase trypsin inhibitors (5). A study with Double Blind Placebo Controlled Food Challenges by Lundin et al. (6) has been published but with inconclusive results. Given this background, contrary to CD, factors involved in the etiology of NCGS are still unknown. In a search for biomarkers and perhaps even contributing factors for NCGS, a microbial signature of the gut would be a good candidate.
METHODS Study Design In a population based on healthy adolescents we conducted a double blind placebo controlled food challenge (DBPCFC) with cross-over to identify patients with NCGS as recommended by the Salerno criteria(1). It will take place at Hans Christian Andersen Childrens Hospital at Odense University Hospital, Denmark in November 2020. It was approved by The Regional Committees on Health Research Ethics for Southern Denmark (project no S-20160061) and the Danish Protection Agency (2008-58-0018).
Study Population The adolescents were participants in the GlutenFunen cohort, which were recruited from an unselected subsample of the Danish National Birth Cohort, defined as those living on the Island of Funen, Denmark. The Danish National Birth Cohort consists of approx. 96,000 children, who are followed from intrauterine life and onwards (most recent follow-up is 18-years follow-up)(7). Their mothers were recruited from 1996 to 2002 from the general population with a participation rate of approximately 30%.
The GlutenFunen cohort included 1266 out of the 7431 eligible participants (17%), in the age 15-21 years old and were examined for Coeliac Disease, anthropometric and metabolic measurements. Furthermore, the participants in the GlutenFunen cohort answered a questionnaire about their gastrointestinal symptoms, and a score based on the number of gastrointestinal symptoms was calculated. Criteria for inclusion was a score higher than three, in total 273 participants. They were all contacted by phone by the author NS or CC and invited to an information meeting where a dietician instructed how to follow a gluten free diet.
Exclusion criteria were wheat allergy, transglutaminase IgA higher than reference range, Inflammatory Bowel Disease and current antibiotic treatment Study Intervention The study was arranged in two phases. See figure 1. The first phase began with a run-in period of seven days to adapt the gluten free diet, subsequent one week of gluten free diet. If the participants responded to the gluten free diet defined as a VAS score higher than 25% compared to initial VAS score the participants proceeded to phase two.
Phase two consisted of three periods each lasting seven days; The first being a challenge with gluten/placebo, then a wash-out phase, and finally the second challenge with placebo/gluten. During the whole study, the participants had to follow a strict gluten free diet. Adherence was not evaluated during the trial, but the participants were asked to note whether they accidentally had eaten gluten.
The granola bars The participants had to eat two granola bars every day except for the wash-out period. The granola bar was lactose free and low in FODMAPS and the amount of gluten in the gluten containing granola bar was 5.0g. The recipe was kindly provided by Lundin et al. (6). In a triangle test there were no difference regarding taste, look and consistency between the gluten and the placebo granola bar.
Outcome measures Gastrointestinal symptoms were measured with a self-administrated 10 items questionnaire, which represented a modified gastrointestinal symptom rating score. It was assessed on a 100mm visual analog scale (VAS) (1-100) at day 1 and 13 and day 15-35. A total score was calculated as the mean of the 10 items. Extraintestinal symptoms and mental health symptoms were measured with SF-36 and the Warwick-Edinburgh Mental well-being scale (14 items) at day 1, 14, 21, 28 and 35.
The Microbiome The participants had to deliver a faecal sample at day 1, 14, 21,28 and 35. To ensure a high compliance the faecal sample was collected at the home of the participants. The faecal sample was frozen immediately, as described previously (8).
Randomization and blinding. The participants were randomised to placebo-gluten or gluten-placebo in blocks of four by the randomization module in RedCap administrated by the data-manager of the study. The kitchen of Odense University Hospital baked the granola bars and packed them in different boxes with two colours to ensure the blinding of the study for the investigators and the participants. The randomization code was not revealed before the end of the trial.
Outcome The primary outcome was identifying participants with NCGS defined as a 30% worsening of symptoms when eating gluten compared to the placebo based on the modified VAS score.
The secondary outcome was an improvement in the mental health of the participants when living on the gluten free diet.
The tertiary outcome was to identify microbial signatures in patients with NCGS.
Statistical analysis Normally distributed data were described with means and the standard deviation and they were compared using paired t-test. Non-parametric data were described with median and percentiles and compared using Mank-Whitney Rank sum test ??. P-values < 0.05 was considered significant.
Power Assuming a positivity of 30% to the challenge, a power of 80% and a significance level of 5% we calculated a need for 29 participants.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: active - placebo intake of socalled gluten bars two daily for seven days, followed by one week wash-out, and then placebo bars for seven days |
Diagnostic Test: positive test followed by gluten-free diet
DBPCFC with gluten
Dietary Supplement: Placebo
Placebo
|
| Placebo Comparator: placebo - active intake of placebo bars two daily, followoed by wash-out for one week, and gluten bars (experimental) for seven days. |
Diagnostic Test: positive test followed by gluten-free diet
DBPCFC with gluten
Dietary Supplement: Placebo
Placebo
|
Outcome Measures
Primary Outcome Measures
- symptom VAS score [one week]
score from 0-100
Secondary Outcome Measures
- specific symptoms [one week]
questionnaire
Eligibility Criteria
Criteria
Inclusion Criteria:
- positive questionnaire of at least 3 predefined symptoms, from cohort study
Exclusion Criteria:
- not 3 predefined symptoms, from cohort study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Steffen Husby | Odense | Denmark | DK-5000 |
Sponsors and Collaborators
- Odense University Hospital
Investigators
- Study Director: Steffen Husby, M.D., Odense University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- OUH-HCA 004